Advocating the need of a systems biology approach for personalised prognosis and treatment of B-CLL patients by Tummala, Hemanth et al.
BioDiscovery
BioDiscovery | www.biodiscoveryjournal.co.uk December 2012 | Issue 6 | 41
REVIEW ARTICLE
Advocating the need of a systems biology approach for 
personalised prognosis and treatment of B-CLL patients
Hemanth Tummala1, Alexey Goltsov1, Hilal S Khalil1, Anne Sproul2, Fiona Scott2, Vanio 
Mitev3,  Nikolai Zhelev1*
1School of Contemporary Sciences, Kydd Building, University of Abertay Dundee, Bell street, Dundee, DD1 1HG, United Kingdom
2Department of Haematology, Western General Hospital, Edinburgh, EH4 2XU, United Kingdom
3Department of Chemistry and Biochemistry, Medical University of Sofia, 1431 Sofia, Bulgaria
Citation: Tummala H, Goltsov A, Khalil HS, Sproul A, Scott F, Mitev V et al. Advocating the need of a systems biology approach for 
personalised prognosis and treatment of B-CLL patients. Biodiscovery 2012; 6: 4; DOI: 10.7750/BioDiscovery.2012.6.4
Copyright: © 2012 Tummala et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, provided the original authors and source are credited.
Received: July 14, 2012; Revised: October 07, 2012;  Accepted: December 23, 2012; Available online/Published: December 30, 2012
Keywords: B-CLL, cancer, systems biology. 
*Corresponding Author: Nikolai Zhelev: e-mail: N.Zhelev@abertay.ac.uk
Conflict of Interests: No potential conflict of interest was disclosed and there is not any competing financial interest in relation to the work 
described.
Abstract
The clinical course of B-CLL is heterogeneous. This heterogeneity leads to a clinical dilemma: can we identify 
those patients who will benefit from early treatment and predict the survival? In recent years, mathematical 
modelling has contributed significantly in understanding the complexity of diseases. In order to build a 
mathematical model for determining prognosis of B-CLL one has to identify, characterise and quantify key 
molecules involved in the disease. Here we discuss the need and role of mathematical modelling in predicting 
B-CLL disease pathogenesis and suggest a new systems biology approach for a personalised therapy of B-CLL 
patients. 
1. Introduction
B-cell chronic lymphocytic leukemia (B-CLL), is the most 
common leukaemia in the western world.  It is not curable 
[1] and the ability of radiation and chemotherapeutic 
agents to induce clinically significant regression of the 
disease in patients with CLL has not improved for the last 
decades [2]. The development of treatment approaches 
for B-CLL has lagged in comparison to other hematologic 
malignancies for various reasons. B-CLL disease seems 
especially prone to familial occurrence being nearly 3 
times higher than that expected for the general population 
[3]. Historical reports exists for identical twins [4], mother 
and son [5], grandfather, son, and grandson [6] affected 
due to familial aggregation of chronic lymphocytic 
leukaemia pathogenesis associated with immune defects. 
In 1980 Conley et al [7] reported an increasing frequency 
of B-CLL disease associated with autoimmune diseases, 
concluding that genetic factors in these families are 
the prime cause of deregulation in the immune system. 
Many reports from the Swedish family cancer database 
[8] evidently reported that there is significantly increased 
familial risk involved in B-CLL disease pathogenesis. 
CLL risks were similar in parents, siblings, and offspring 
cases, and in male and female relatives. They were not 
affected by the case’s age at diagnosis. 
Although prognostic markers have been identified, 
there is as yet no proven indications for initiating treatment 
in patients with asymptomatic disease.. The lack of 
accuracy in predicting disease progression and survival 
on an individual basis has been a long asked research 
question in B-CLL. It’s a known fact that in B-CLL 
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disease pathogenesis to date, no single biomarker has been 
useful in predicting the prognosis in CLL patients. This 
review focuses on our current understanding of clinical 
course and molecular mechanisms in B-CLL disease, 
and suggests the application of systems biology as an 
approach in personalized treatment for B-CLL patients.
2. Clinical paradigm
The clinical course of B-CLL disease is highly variable, 
with life expectancies ranging from months to decades. 
There is no apparent survival advantage for early 
treatment intervention, and some patients may never 
require treatment. At present the information available 
is only used to counsel patients and to help inform 
clinicians regarding the frequency of monitoring. The 
currently available clinical staging systems (e.g. Rai or 
Binets test) for B-CLL are simple and inexpensive but 
lack accuracy to predict disease progression and survival 
on an individual basis. Prediction was not significant 
when analyzed using life table methods performed by 
Goldin et al. [8] and it is thereby concluded that the 
familial component of CLL is shared with other lympho 
proliferative malignancies, suggesting common genetic 
pathways. As infection is a major cause of morbidity 
and mortality in B-CLL, previous studies on infection 
predictors in CLL were based on patients receiving 
chemotherapy, or on those diagnosed with infections 
during the ‘watch and wait’ period and during therapy 
[9-12]. Treatment strategies in preventing recurrent 
infection procedures in these patients, however, have not 
yet been devised [13]. 
B-CLL disease is characterized by an accumulation 
of mature, non-proliferating B lymphocytes in the blood, 
spleen, lymph nodes and bone marrow. The accumulation 
of B cells is the result of a proliferative defect, failing B 
cells to undergo apoptosis and leading to large numbers 
of cells being blocked in the G0/G1 phase of the cell 
cycle [14]. Not surprisingly, many studies have shown 
that B-CLL cells are resistant to various drug induced 
apoptosis [15]. The reasons for this are unclear, but may 
include a combination of various factors like reduced 
expression of several apoptosis inducing proteins that 
include receptors, kinases and enzymes. 
The diagnosis of B-CLL is carried out using a 
number of classic and novel sensitive techniques, 
which allow diagnosing and differentiating the disease 
from other chronic lympho proliferative disorders [16-
18]. Morphology and immuno phenotype are the initial 
diagnostic investigations, alongside molecular genetics 
and/or histology to exclude other B cell disorders. To 
date immuno phenotyping is the only method that can 
determine or confirm the diagnosis, as B-CLL lymphocytes 
carry a distinct immuno phenotypic signature (more than 
5 x 109 B cells/litre). A scoring system compounding the 
results with a set of markers allows a refined confirmation 
of the diagnosis as described by Matutes et al. [18], but 
this scoring system cannot be applied globally to patient 
management, as the B-CLL disease heterogeneity exists 
irrespective of mutated and unmutated pattern of the 
IgVH region.  
B-CLL disease has been presented as two distinct 
types. The presence of somatic mutations in the 
immunoglobulin (IgH) heavy chain gene define a group 
of patients exhibiting stable or slowly progressive 
disease that requires late or no treatment.  By contrast, 
the absence of mutations in the IgH genes of B-CLL cells 
define a group, which exhibit a progressive clinical course 
requiring early treatment [19]. Other immunological 
markers such as surface antigens (for example, CD38 
and ZAP-70) have an important prognostic impact but 
still lack accurate prediction in patient survival rates and 
overall treatment response rates. Moreover, optimal drug 
administration schedules are required in order to improve 
clinical response in CLL patients.
3. Cell cycle, proliferation and apoptosis
B-CLL lymphocytes lack the fundamental functions of 
regulating the cell cycle and apoptosis. That is why the 
cellular factors that govern the entry of resting B-cells 
into the cell cycle and promote their progression through 
the different phases of cell cycle, are considered to be 
optimal targets for drug therapy. Normally the matured 
naive lymphocytes circulating in blood remain quiescent 
in the G0 phase and reside in lymphoid tissues such as 
the spleen until they encounter an appropriate mitogenic 
stimulus. The progression of the cell cycle in naive B 
cells depends on the PI3K activation of AKT activation, 
and inducing NF-kB activation and cyclin D2 activity by 
deregulating FOXO transcription rate [20-21]. The rate 
at which B lymphocytes enter the cell cycle is tightly 
regulated by a very complex process involving multiple 
components of the cell cycle machinery, apoptosis, and 
the antibody-generating apparatus and by downstream 
effectors of Bcl-2 pathway (e.g. caspases). 
The proliferation rate and resistance to drug-induced 
apoptosis in B cells are recognized as important factors 
in the outcome of treatment in CLL disease. Mutated 
and unmutated CLL patients clearly differ in terms of 
prognosis. The genomic aberrations occurring in B-CLL 
patients have their individual effects due to distinct 
expression profiles, as reported by Klein et al [22]. This 
is termed as gene dosage effect, which is correlative with 
the variable mutational status of IgVh [23]. CLL cells are 
dependent on the continuous expression of intrinsically 
short lived anti-apoptotic proteins for survival. This 
biological context has been a promising strategy to 
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induce apoptosis by the inhibitors of transcription and 
translation. High levels of Mcl-1 and Bcl-2 mRNA [24] 
and protein [25] have been found in B-CLL. Mcl-1 is 
associated with the failure in response of B-CLL patients 
to initial therapy, due to its high expression [26, 27] 
whereas low expression of Mcl-1 in CLL cells is related 
to prolonged patient survival [24]. The presence of Bcl-
2 (B-cell B-CLL/lymphoma 2), an anti-apoptotic protein 
that is highly expressed in B-CLL, and which cannot 
be neutralised with the levels of pro-apoptotic proteins, 
has been a characteristic feature for B-CLL cells when 
compared to normal B cells [28]. B-cell antigen receptor 
(BCR) is the key signalling molecule of B-lymphocytes, 
triggering pathways involved in B-cell proliferation, 
survival, differentiation, and apoptosis. In B-CLL, the 
status of the BCR is of important prognostic, biological, 
and therapeutic value. This is reflected in the great variety 
of emerging novel agents targeting the BCR signalling 
cascade. 
To date large components of BCR signalling 
pathways have been elucidated in determining the 
prognosis of B-CLL, but failed to predict accurately. 
Pharmacological inhibition of BCR signalling in CLL 
can be achieved by targeting components of the BCR 
signalling cascade. Several groups have reported an 
increase in MAPK (ERK2) phosphorylation and NFAT 
transcriptional activity and a corresponding lack of AKT 
phosphorylation due to constitutive activation of distinct 
BCR signalling pathways in a subset of particular CLL 
cases [29]. The aberrant signalling mechanism in BCR 
signalling cascade includes the activation of PKC and 
PI3K pathways, which regulate B cells survival. The 
signal transduction inhibitors in these pathways have 
resulted promising results in vitro, but could not be used 
as effective single agents for B-CLL therapy. Existence 
of molecular heterogeneity in CLL that is dependent on 
the expression of genes defining BCR signalling has been 
pivotal, but still lacks in attaining accurate prediction of 
patient survival in clinical course. 
Increased aggregation of B lymphocytes due to a lack 
of apoptotic signalling has been a well known cause in B- 
CLL disease pathogenesis, suggesting that B-CLL cells 
lack the fine tuning of a balance between pro-apoptotic 
and anti apoptotic factors in the microenvironment. 
The anti-apoptotic protein Bcl-2 is highly expressed in 
B-CLL patients and has been well characterized, but 
paradoxically, high levels of pro-apoptotic molecules 
have also been observed [30, 31]. Deregulation of the 
cell cycle regulators (CCND3, CCND1, and MYC) 
and apoptosis regulators (NPAT, CUL5 and PPP2R1B), 
and a role for these genes, has been implicated in the 
pathogenesis of B-CLL disease [32]. Moreover there 
is a rapidly growing number of the modulators of BCR 
components and the cell death machinery. These can 
be targeted to disrupt the turgid balance between pro 
apoptotic and anti apoptotic factors, and restore healthy 
balance, and are considered to be of optimal therapeutic 
value in the treatment of CLL [33, 34].
4. Microenvironment: Cross talk and 
interplay
Microenvironment regulating signals are crucial for 
the process of signaling in leukemic cells that induce 
proliferation and lead to the survival and accumulation 
of leukemic cells within lymphoid organs. The in vivo 
accumulation of leukaemic lymphocytes is potentiated 
by interactions of CLL cells with other cells such as 
mesenchymal stromal cells (MSCs), nurse-like cells 
(NLCs), T cells and other soluble factors that include 
Interleukins (IL-4) and cytokines such as CCL22 and 
CCL17 [35]. CLL cells grow in the microenvironment of 
a solid tissue where they initiate as monoclonal disease of 
autoreactive B cells, due to receptor-ligand interactions 
resembling an autoantigen and neoantigen. A process 
called auto antigen drive has been shown to be essential 
in selecting susceptible B cells out of the normal clone 
and driving them into the disease state [36]. 
Common genetic aberrations that occur in CLL 
disease and different stimuli originating from the 
microenvironment, cooperate in the selection and 
expansion of the malignant clone. CLL cells relentlessly 
accumulate in vivo but rapidly undergo spontaneous 
apoptosis in vitro. This implies that their apoptosis 
resistance, rather than being an intrinsic feature of 
leukemic stage, depends on external signals for survival 
since the maturation stages of B cells are highly dependent 
on microenvironment signals [35]. 
Exemplified crosstalk between CLL cells and 
accessory cells occurs in the marrow and/or lymphoid 
tissue microenvironments. Contact between CLL cells 
and NLCs or MSCs is established and maintained by 
chemokine receptors and adhesion molecules. NLCs 
express the chemokines CXCL12 and CXCL13, whereas 
MSCs predominantly express CXCL12. NLCs and MSCs 
attract CLL cells via the G protein coupled chemokine 
receptors CXCR4 and CXCR5, which are expressed at 
high levels on CLL cells [35]. CD38 expression allows 
CLL cells to interact with CD31, the ligand for CD38, 
expressed by stromal and NLCs. Ligation of CD38 
activates ZAP-70 and downstream survival pathways. 
Self and/or environmental antigens (Ag) are considered 
a key factor in the stimulation and expansion of the CLL 
clone. BCR stimulation and co-culture with NLCs also 
induce CLL cells to secrete high levels potent T-cell 
attracting chemokines such as CCL3 and CCL4. 
Through this mechanism, CLL cells can actively 
recruit T cells for cognate T-cell interactions with CLL 
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cells. CD40L T-cells are preferentially found in CLL 
proliferation centers and can interact with CLL cells via 
CD40. Cytokines secreted by T-cells or CLL cells such 
as TNF-a   or IL-4 are considered important regulators 
of CLL cell survival. Moreover, downregulation of 
proximal and intermediate T-cell receptor signalling 
cascades and globally reduced cytokine secretion, 
contributes to significant immunodeficiency in non-
leukemic indolent B-cell lymphomas [37]. Collectively, 
this crosstalk between CLL cells and accessory cells 
results in activation of survival and drug resistance 
pathways [36]. Focusing on the therapeutic aspect of 
regulating the microenvironment, this includes disruption 
of targets in the complex interplay between CXCR’s 
and adhesion molecules, which is the precise definition 
of systemic T-cell dysfunction. This might eventually 
provide a rationale for appropriately tailored molecular 
therapies targeting not only B-CLL cells but also the 
microenvironment, to ensure improved treatment.
5. Micro RNAs
Micro RNA’s (miRNAs/miR’s) are a recently discovered 
class of molecules that regulate gene expression at 
the posttranscriptional level. The interactions between 
miRNAs, target genes, and pathways in CLL are clearly 
complex, as are the links between genotype and phenotype 
miRNA machinery, which include miRNAs involved 
in many cellular processes such as proliferation and 
apoptosis. Some microRNAs are referred to as oncomiR’s 
and exhibit differential expression level in cancer disease 
by acting as either oncogenes or tumour suppressor genes 
[38, 39]. Recent in vivo studies demonstrated that tumours 
became addicted to oncomiR’s. Their inactivation 
resulted in complete tumour regression, demonstrating the 
importance of miRNAs in therapeutic pharmacological 
intervention (for example miR-21). A role for miR-21 in 
cancer has been implicated strongly by the fact that it is 
overexpressed in haematological malignancies, especially 
B-CLL [38]. Several studies have proposed the use of 
microRNA-based classifications as signature profiles 
for B-CLL disease prediction and survival [41]. miR’s 
studies are likely to have an increasing influence in the 
diagnosis, prognosis and treatment of human cancers, 
including CLL [42].
Cimmino et al. [43] proposed that miR-15a and miR-
16-1 function as tumor suppressor genes by modulating 
Bcl-2. The same miR signature was also associated with 
the presence or absence of disease progression, since Bcl-
2 mRNA stability is not affected by the overexpression of 
these miR’s but instead was regulated by Bcl-2 expression 
at a posttranscriptional level. miR-34a expression has 
been found to be very low in B-CLL patients. B-CLL 
cells with reduced miR-34a expression showed increased 
viability after DNA damage, independently of 17p status. 
Low expression of miR-34a in CLL is therefore associated 
with p53 inactivation as well as chemotherapy refractory 
disease, impaired DNA damage response, and apoptosis 
resistance irrespective of 17p deletion/p53 mutation 
[44]. This study identified the role of miR-34a in B-CLL 
pathogenesis where they speculated that it took over the 
control of apoptotic machinery in both p53 dependent and 
independent pathway by controlling the expression of 
Bcl-2 and p21 [45]. 
The demonstration of down- regulation of cyclin-E2, 
CDK6, E2F5, cyclin D1 (CCND1) and Bcl-2 protein 
levels after induction of miR-34a expression has been 
noted to be important, suggesting that miR-34a in CLL 
mediates its functions within and potentially outside the 
p53 pathway [46]. A recent study report by Asslaber et 
al. [47] showed that a low level of miR-34a expression 
profile predicted a shorter time for treatment of disease 
in B-CLL patients, alternatively an over expression of 
mIR34-a induces apoptosis through p53 attenuation by 
negative feedback loop regulatory mechanism. This study 
specifically indicates that the p53 tumour-suppressor 
pathways and associated miR-34a expression may be a 
promising avenue of research into the pathogenesis and 
prognostic assessment of CLL, and may prove more 
useful in aiding early-stage identification of patients with 
fludarabine refractory CLL. Moreover karyotype specific 
signature profiles have been found to be associated with 
different forms of B-CLL such as indolent and aggressive 
[41]. 
Analysis of miRNA expression values between the 
predefined subgroups showed that the miR-223, the miR-
29b, the miR-29c, and the miR-181 family are down 
regulated in 17p-aggressive cases showing the highest 
level of Tcl-1 expression compared with 17p-indolent cases 
[48]. The findings in this study suggest that interactions 
between Tcl-1 and miRs play an important role and suggest 
them as new markers to assess the disease course in CLL 
patients. Although such findings are exciting, larger 
studies demonstrating reproducibility are still required. 
Targeted miRNA therapeutics remain at the early stages 
of development and are limited primarily to in vitro and 
murine models of disease. Given the fact that miRNA’s 
expression profiles may prove to be novel surrogate 
markers for common cytogenetic lesions, the prognostic 
indicators like karyotype specific signature in B-CLL 
disease is highly difficult to achieve through miRNA 
based therapy. To conclude, micro RNA studies indicate 
the importance of considering more than one parameter 
to assess the tumour burden in B-CLL, but could not 
advocate a replacement of standard clinical and molecular 
markers. The research findings suggest that the addition of 
the miR’s expression is critical for the evaluation and more 
accurate management of CLL patient care.
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6. Drug targets and resistance
Adequate progress has been made in recent times for 
therapeutic intervention and management B-CLL disease. 
New insights into the molecular pathology of B-CLL 
have generated a plethora of biological markers that 
predict the prognosis and influence therapeutic decisions. 
These markers include historical Rai and Binet staging 
systems, loss of p53 and ATM functions, the unmutated 
IgVH gene, and high expression of ZAP-70 or CD38 
[49]. These factors in B-CLL cells have been identified 
as unfavourable prognosis to standard chemotherapy or 
are indicative of aggressive disease. Several strategies 
that induce apoptosis and circumvent resistance by a 
combination of inhibitors of transcription and translation 
such as CDK inhibitors, together with other approaches 
that interfere with the function of anti-apoptotic proteins 
that initiate synergistic killing in B-CLL (flavopiridol, 
R-Roscovitine, Danciclib and SNS-032) have been 
employed [50-53]. 
A recent review by García-Escobar et al. [54] stated that 
preclinical evidence for the efficacy of signal transduction 
inhibitors such as alkylating agents [55] and purine 
analogues [56] in B-CLL is particularly encouraging, but 
the results of clinical trials on using these as single agents 
have not been satisfactory. Combinational therapy on the 
other hand has been proved efficacious and is currently 
being explored in pre-clinical studies and early-phase 
clinical trials. These have not been used routinely in the 
clinic because they exhibit differential responses due 
to poor diagnostic and prognostic marker relevance. To 
date drugs like fludarabine, bendamustine and the two 
monoclonal antibodies, alemtuzumab and rituximab have 
been approved by European and/or American regulatory 
agencies. Monoclonal antibody Alemtuzumab holds a 
promising combination of therapeutic modality with 
fludarabine as a first line treatment for refractory CLL 
patients. Recently haematopoietic stem cell transplantation 
such as low toxic non-myeloablative allogeneic transplant 
has opened new perspectives in the management of CLL 
patients, and appears to be a promising therapy for elderly 
patients. 
Additional monoclonal antibodies targeting CD20, 
CD23, CD37, CD38 or CD40, as well as drugs designed 
to interfere with proteins regulating the cell cycle, 
apoptotic machinery or leukemic microenvironment 
(e.g., flavopiridol, oblimersen, ABT-263 or lenalidomide) 
are being investigated in clinical trials. To date, single-
agent clinical trials have indicated that the major clinical 
outcome is the stabilization of disease states. Lyse [57] 
showed that pre-treatment of TRAIL resistant B-CLL 
cells with histone deacetylase inhibitors such as Oxam, 
rendered cells to be susceptible for subsequent killing by 
recombinant TRAIL protein. This therapy preferentially 
increased surface expression of TRAIL-R1 and 
TRAIL-R2, there by leading to caspase 8 and caspase 
3 activation. Importantly, this is a combination therapy 
that enables preferentially sensitized transformed cells to 
apoptosis. Recently Niedermeier et al. [58] and Herman 
et al [59] demonstrated that the isoform-selective PI3K 
inhibitors induced B-CLL cell apoptosis in vitro in MSC 
co-cultures synergized with fludarabine induce B-CLL 
cell apoptosis. Thus, combination therapies using specific 
and recombinant inhibitors in signal transduction pathway 
might prove to be efficacious for the treatment of B-CLL. 
The main focus of therapeutic strategies in B-CLL is 
still cytotoxic chemotherapeutically available alkylating 
agents or purine analogues that trigger DNA damage 
response via p53 leading to a prominent cell death. Most of 
B-CLL diseased patients carry defects in the p53 pathway 
and therefore it has been challenging to overcome the 
resistance through p53 independent cell death pathways 
[60, 61]. Drug- induced resistance to B-CLL treatment 
enhances by activating survival signaling pathways 
(for example NF-kB) through activation of PI3K-Akt 
and therefore counteracting the effect of the treatment. 
Microenvironment plays major roles in B-CLL tumour 
resistance to therapies. Most of the factors and pathways 
discussed above that are responsible for sustained 
activation of survival pathways in B-CLL are provided by 
contact with the microenvironment.
7. Systems biology approach
Although clinical stages such as Rai and Binet tests 
are the required basis for the prognosis in the B-CLL 
patients, many other biological markers mentioned in 
the above section have been offering important insights 
to prognostic information. Nonetheless these prognostic 
factors have not been fully validated or standardized in 
large clinical trials. Moreover, it is practically impossible 
to validate all possible biomarkers in clinical trials due to 
the fact that response upon drug dosage in B-CLL patients 
is varied, and therefore could not sustain in clinical 
evaluation. Existence of conflicting data in research 
studies has added more complexity and confusion in the 
evaluation of B-CLL disease pathogenesis. For example 
Klein et al [22] reported that a large number of apoptotic 
genes deregulated in particular with 17p deletion, which 
reflected the distinctly aggressive biology of a subgroup 
cohort study in B-CLL patients and contrasted with reports 
published by Stankovic et al [62] and Schaffner et al [63], 
showing an indistinguishable native gene expression 
pattern in terms of quantitative folds when comparing 
wild type and TP53-mutant in B-CLL cells acquired from 
patients. 
Notably, Klein et al [22] used highly sensitive 
quantitative RТPCR approach and a greater number of 
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case studies in evaluating the data, when compared to the 
Stankovic et al. [64] microarray study. Moreover, low Bcl-
2 levels in 17pdel, the subgroup with the worst clinical 
course was reported by Klein et al [22] due to the known 
anti-apoptotic function of Bcl-2 and the association of 
high Bcl-2/BAX ratios with aggressive disease, which 
argues against a relevant role of Bcl-2 overexpression 
or elevated Bcl-2/BAX ratios in the pathogenesis of 
the B-CLL or in B-CLL prognosis. The Kim et al. [65] 
study supported the use of a whole genome sequencing 
approach for comprehensively decoding the B-CLL 
genome in order to better understand the genetic defects 
caused by insertion, deletion, base change, and restriction 
site polymorphism present in both coding and non-
coding regions in hundreds of loci within the genomes, 
which indicate the wide presence of small genomic 
aberrations in B-CLL. B-CLL cases display recurrent 
genetic aberrations including trisomy 12 and monoallelic 
or biallelic deletion/inactivation of chromosomal regions 
17p, 11q and 13q14 [66]. Presently these deletions and 
the mutational status of the IgVH gene provide prognostic 
information and may determine the type of therapy [67].
The above mentioned molecular signatures may 
have a profound impact on prognosis for B-CLL disease 
pathogenesis, but the lack of routine clinical methods for 
diagnosis is a major challenge which should be accounted 
for in future research. Taking into consideration our 
current understanding of B-CLL disease pathogenesis, 
it is now convincing that application of systems biology 
should be employed as an approach for predicting 
patient response and designing individualized therapies. 
An iterative interplay between biological experiments 
producing quantitative data followed by suitable modeling 
strategies should enable us to interpret the biology in a 
global system perspective, thereby increasing our current 
understanding of the signaling pathways involved in the 
pathogenesis of a complex disease such as B-CLL. This 
approach should also include the extracellular aspects of 
the disease mechanism such as microenvironment. Due to 
the fact of these differential study conclusions, it is now 
time to consider prognosis and treatment on an individual 
basis rather than cohort studies involving large numbers 
of patients. Moreover it is now evident that B-CLL is not 
a single target regulated disease, but rather has multiple 
targets with two distinct disease phenomenae (indolent 
and aggressive forms). 
Building network models by applying systems biology 
is an approach that will enhance our understanding of key 
molecular players in the B-CLL disease pathogenesis. 
To generate a computational model for prognosis 
of B-CLL patients in silico, one has to overcome a 
number of challenges such as working with a large 
number of chemically diverse molecules that are often 
rapidly changing their concentrations in terms of their 
expression and regulation [68]. In order to overcome 
these challenges, various sensitive detection systems or 
gene reporter systems should be implemented to detect 
the optimal expression in vivo [69] before its execution in 
building a model. It is clear from the many experiments 
and studies carried out to date that there are no single 
genetic or molecular aberrations which alone lead to the 
B-CLL phenotype. 
Disease progression can vary considerably from one 
patient to another suggesting that future therapies will 
need to be designed on an individual basis. To do this, 
it requires an in-depth analysis of two major groups 
of variables. Firstly by encompassing the molecular 
interactions between the various intra-cellular proteins 
which implement the cell’s regulatory pathways, in 
particular survival, anti-growth, proliferation and 
apoptosis (Figure 1). Secondly, as these interactions are 
highly complex at the intra-cellular level where the loss 
of homeostasis has to be analysed, a model reporting on 
the molecular activity, and the imbalance between B-cell 
proliferation and apoptosis should be addressed. Due to 
this complexity, some form of holistic approach to the 
problem is required and we believe that one way forward 
is to describe the dynamics of the various molecular and 
cellular interactions by using a mathematical model. In 
this way the mechanistic links, which underpin the B-CLL 
disease phenotype can be defined and, subject to calibration 
at the individual patient level, these models would enable 
a better understanding of disease progression, as well as 
providing a methodology for targeted drug interventions.
The key aspects in cellular signaling that involve the cell 
cycle, apoptosis and various intracellular pathways such 
as DNA damage repair and cytokine receptor activated 
network activating PI3K/AKT, are considered to be crucial 
components that are frequently deregulated in B-CLL 
disease. Each pathway is subject to an intensive study by 
the computational systems biology approach: modelling 
of the cell cycle [65-73], apoptosis [74-76], MAPK and 
PI3K/AKT pathways [77, 78]. As these pathways are 
involved in cell proliferation, survival and cell death, 
computational models of these pathways are considered 
promising tools in cancer research for prediction of cancer 
disease progression, development of biomarkers, and 
drug therapy efficacy [79-82]. Henceforth, understanding 
the complex regulation of B-CLL disease pathogenesis, 
requires a strategic knowledge on the models of the cell 
cycle, and apoptosis that report on intrinsic and extrinsic 
cell signaling network. Systems computational approach 
to the complex regulation in B-CLL pathogenesis is now 
at the initial stage of development. We discuss below 
recent results from computational modeling of these 
pathways and address some specific results relevant to 
B-CLL disease. 
The mathematical approach to modelling the cell 
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Figure 1. An extract of the intra-cellular network, frequently deregulated in B-CLL disease. The diagram shows the interactions upon 
ligand stimulation of TRAIL, FaS, BAFF and APRIL receptors and the activation of key proteins that are involved in regulating B-cell 
apoptosis or survival by regulating gene transcription. It illustrates the function of Mdm2 and P53 as activators of various cell cycle check-
points regulating proteins such as CHK2, CHK1 and DNA damage repair enzyme ATM and ATR. Regulation of this network can lead to 
growth arrest and DNA repair in promoting cell survival. Any aberration in these parameters induced by drug will induce caspase activation 
by its upstream target Bcl2/Bax and Mcl-1. The construction of mechanistic models of the underlying dynamics could enable better targeted 
drug therapy.
cycle was developed in a series of works by Novak and 
Tyson [70, 83, 84], which demonstrated that the cell cycle 
could be modelled as an irreversible sequence of changes 
between successive steady states, driven through changes 
in cyclin levels and loss of their stability at cell cycle phase 
transition. Further development of this approach was 
made in a series of models which successively described 
key features of cell cycle dynamics, and predicted main 
control mechanisms of the transitions in the cell cycle (see 
a review of cell cycle models in [85]. The general result 
of cell cycle modelling showed the extreme robustness of 
cell cycle function at a wide variation of model parameters 
such as protein-protein interaction constants, rate 
constants of protein phosphorylations, protein expression 
and degradation rate constants [70, 80, 81]. These findings 
are in accordance with experimental observation that the 
cell cycle is one of the highly controlled processes in the 
cell [84]. The decision making for cell division, its delay, 
arrest or apoptosis is tightly orchestrated by integrating 
both external cellular signals, such as growth factors and 
hormones, and internal signaling molecules. Cell cycle 
modelling demonstrated that despite extensive control 
mechanisms in regulating phase transitions, it can lose its 
control and become a fragile system when variations in 
specific parameters of the model that affect robustness are 
introduced. From a clinical point of view, this fragility in 
the system can be referred to as cell cycle malfunction, 
observed as uncontrolled cell proliferation, a common 
phenomenon underlying many cancers [82]. 
7.1 Identification of fragile nodes
In this context a new area in systems biology is being 
developed that aims at not only the description of the 
normal functioning of cellular control  systems, but also 
the modelling of the mechanics of their malfunction in 
pathological conditions including cancer [74, 81, 86]. 
Novel approaches were designed to analyze the existing 
models of the cell cycle to study the abnormality in 
its control mechanisms leading to uncontrolled cell 
proliferation and survival, causing diseases including 
solid and hematological cancers [80, 82]. One of the 
challenges in systems biology is in determining the 
fragile, sensitive nodes of signaling pathways, including 
the cell cycle regulation, which cause the disruption of 
the balance between cell proliferation and death. These 
fragile points are suggested as control hubs within cellular 
signaling networks, which are extremely sensitive to 
mutations or the aberrant protein expression observed in 
cancers [82]. These fragile hubs, possessing increased 
sensitivity to internal perturbations, are assumed to also 
be sensitive to external perturbations such as drug action. 
Fragile points in signaling networks therefore represent 
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promising targets for drug intervention [80-82]. 
One of the powerful methods for determining fragile 
nodes within cellular signaling networks is sensitivity 
analysis of the computational models [79, 82]. Sensitivity 
analysis of the model consists of the calculation of 
sensitivity coefficients: ‘S’ which represents the response 
of a network output, ‘DY’ to a variation of model 
parameters, ‘Dp’ (protein-protein interaction constants, 
rate constants of protein phosphorylation, protein 
expression, degradation rate constants, others): S=DY/
Dp. Sensitivity analysis permits ranking sensitivity of 
different outputs of the model to variations of the model 
parameters and determining a network locus which is most 
sensitive to these perturbations. Points in the network that 
exhibit extreme sensitivity to small perturbations of the 
parameters are often referred to as ‘‘fragile’’ (the converse 
of ‘‘robust’’) [74, 80].
The results of sensitivity analysis of the cell cycle 
models obtained by Nayak S et al. [82], screened for 
fragile mechanisms in the existing cell cycle models using 
sensitivity analysis and predicted that such mechanisms 
are implicated in various solid and hematological cancers 
including B-CLL. The sensitivity coefficients calculated 
in sensitivity analysis [82] of the G1/S model of Qu et 
al. [71] and the G2/M-DNA damage model of Aguda 
[72] are shown in figure 2. Sensitivity coefficients with 
high ranks showed that the following reactions can be 
classified as the most fragile steps in the G1/S checkpoint: 
1) dephosphorylation of CDC25, 2) expression of cyclin 
E, 3) degradation of the cyclin E-CDK2 complex, and 4) 
level of the transcription factor E2F. Experimental and 
clinical data supported the computational identification 
of the fragile reactions in the cell cycle which represent 
promising targets for drug therapy. The first ranked 
reaction is the activation of CycE-Cdk2 by CDC25 
phosphatases in the G1/S network. The significant role 
of CDC25 phosphatase was observed in many solid and 
haematological cancer progressions, and several CDC25 
inhibitors showed promising results in cancer treatment 
[82]. 
The second ranked fragile mechanism in the G1/S 
network obtained in sensitivity analysis is cyclin E-CDK2 
complex. Inhibition of the active cyclin E-CDK2 is being 
considered as a treatment strategy in different types 
of cancer including B-CLL. For example, a synthetic 
flavone, flavopiridol induces cell cycle arrest by inhibiting 
multiple CDKs, and leads to p53-independent apoptosis 
in CLL cells [87]. The first ranked fragile points in the 
G2/M-DNA damage network is the activation of preMPF 
(cyclin B–CDK1 complex) catalyzed by CDC25 [82]. This 
Figure 2. Sensitivity analysis of cell cycle models. Sensitivity coefficients [82] determined for the G1/S model [66] (A) and the G2-DNA 
damage model [67] (B). Abbreviations: CycE - cyclin E, aCycE/iCycE – active/inactive CycE, CDC25 - a dual-specificity phosphatase 
CDC25A, aCDC25/iCDC25 – active/inactive CDC25, Cdk2 - cyclin dependent kinase 2, E2F – transcription factor E2F, CKI - a cyclin 
dependent kinase inhibitor, aCKI/iCKI – active/inactive CKI, pRB - retinoblastoma protein, CycD - cyclin D, Cdk4/6 – cyclin dependent 
kinase 4 or 6, pMPF - pre-maturation promoting factor, p21 - cyclin-dependent kinase inhibitor,  14-3-3s - 14-3-3s protein, Wee1 - Wee1 
kinase. Data are represented by courtesy permission of Prof. J.D. Varner. 
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finding correlates with the CLL treatment by bryostatin-1, 
a protein kinase C (PKC) inhibitor and antagonist of 
cyclin B-CDK1 complex [88]. The other types of fragile 
mechanisms obtained in sensitivity analysis [82] are 
related to protein synthesis and degradation (see sensitivity 
coefficients for concentrations of E2F, synthesis of CycE, 
CDC25, and other proteins in figure 2). Targeting these 
mechanisms now becomes an active area of therapeutic 
strategy by developing the manipulation methods of 
translational machinery and programmed proteolysis [82]. 
7.2 Signalling simulation models
The signaling pathway relevant to B-CLL disease is 
PI3K/AKT pathway, which plays a key role in cell 
proliferation, differentiation and survival [58, 59]. 
Constitutive activation of this pathway by chemokine and 
cytokine receptors in CLL cells results from interaction 
of leukaemia cells with their environment, mainly due 
to chemokines secreted by stromal cells, which activate 
CXCR4 receptors and downstream pro-survival PI3K/
AKT signaling [89]. Computational modeling of the PI3K/
AKT pathway was a subject of many theoretical studies, 
which focused on different aspects of the complexity in 
this signaling pathway [77, 78, 90-92]. Development of 
large-scale models of the PI3K/AKT network, reported the 
response of the signaling network upon different cytokine 
stimuli [91] and elucidated the control mechanisms in 
AKT signaling cross talk with other pathways [92]. The 
application of the computational modeling of PI3K/AKT 
signaling in cancer research [93] is aimed at the description 
of activation signaling in different cancer cell lines [78], 
Figure 3. Sensitivity analysis of the PI3K/AKT signaling model [91]. Representation of sensitivity of phosho-AKT signal to kinetic 
parameters: rate constant ki, dissociation constants Kd,i, maximal rate of reaction Vm,i, and Michaelis-Menten constants, Km,i (A) and to the 
initial concentrations of the enzymes (B). Abbreviations: AKT - protein kinase B, pAKT – phosphorylated AKT, PI3K - phosphatidylinositol-
3-kinase, PTEN - phosphatase and tensin homolog, PDK1 - phosphoinositide-dependent protein kinase-1, PP2A - protein phosphatase 2A, 
PIP3 - phosphatidylinositol (3,4,5)-trisphosphate, PIP2 - phosphatidylinositol 4,5-bisphosphate.
analysis of the roles of cancer-driven mutations in this 
pathway [78,94], modeling of the response of the pro-
apoptotic signal to anticancer drugs [78, 92], elucidation 
of mechanisms of drug resistance [95], identification of 
drug targets, [78, 96], optimization of anticancer therapy, 
and also the development of combination therapy [78, 
97]. 
Sensitivity analysis of these models being a powerful 
method for analysing PI3K/AKT signaling in cancer 
was carried out in many works to identify fragile points 
in this pathway [78, 91, 96, 97], to determine sensitivity 
of the pathway to different mutations involved [97], and 
to find promising drug targets [78, 96, 97]. Note the 
different methods of sensitivity analysis used in different 
works [78, 91, 96, 97]. Below we discuss the results of 
sensitivity analysis of PI3K/AKT pathway model carried 
in [96, 97], which can be used to analyse drug targets 
within this network. 
The results of sensitivity analysis of the PI3K/AKT 
pathway model [97] are given in figure 3. The comparative 
analysis of sensitivity coefficient ranking for different 
network modules revealed that one of the most sensitive 
loci within this network is the PI3K/PTEN cycle which 
forms a regulatory hub within cellular signaling. It includes 
PI3K and phosphatase PTEN, which jointly control the 
pool of the second lipid messenger, phosphatidylinositol-
3,4,5-trisphosphate (PIP3). This conclusion is in 
agreement with the results of an integrative genomic 
and proteomic analysis of solid [98] and haematological 
cancers [99] which revealed that this regulation hub is 
vulnerable to mutations in cancer. PI3K is considered an 
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attractive treatment for targeting several types of cancers 
including B-CLL [89]. The recent development of specific 
PI3K inhibitors targeting different PI3K catalytic subunits 
enable the inhibition of the p110δ isoform of PI3K, which 
is reported to be specific to hematopoietic cells [58, 89]. 
Clinical testing of CAL-101, a selective inhibitor of the 
PI3K p110δ isoform showed a suppression effect on 
stromal cell-derived survival of CLL cells [89, 100]. 
7.3 Apoptosis simulation models
The high sensitivity of PI3K/AKT signalling to AKT 
expression level revealed in sensitivity analysis (see figure 
3B) showed its significant impact to anti-apoptotic signal. 
Activated AKT inhibits apoptosis by phosphorylation 
of Bad protein, procaspase-9, and involves in NF-kB 
activation, so AKT inhibition is an attractive target for 
CLL drug therapy. Preclinical trials showed that AKT 
inhibitor, A-443654 induces apoptosis in B-CLL cells 
[101, 102]. The cell cycle and PI3K/AKT pathways 
discussed above are directly connected to the apoptotic 
signalling pathway which plays a significant role in the 
pathogenesis in B-CLL, and is considered an attractive 
target in the development of novel strategies in CLL 
therapy [89]. 
A large number of theoretical studies are devoted to 
computational modelling of both the intrinsic and extrinsic 
apoptotic pathways [74, 75, 103-110]. The theoretical 
modeling of intrinsic apoptosis pathways are focused in 
part on apoptosis induced by DNA damage signals, and 
includes the description of p53-Mdm2 pathway with 
ATM/CHK2,  ATR/CHK1 and p21 components, which 
regulate DNA repair, cell cycle arrest, and apoptosis (see 
figure 1) [80, 104, 106, 108]. Sensitivity analysis of p53-
Mdm2 pathway models showed that the dynamics of the 
DNA damage response are sensitive in part to the level of 
p53 which dynamically changes in different cells [106, 
108]. The fragility of the DNA damage pathway leading 
to promoted cell survival and genome instability, can play 
a particularly significant role in pathogenesis of B-CLL 
[89]. TP53 mutations are considered to be biomarkers of 
the overall survival, treatment-free survival, and relapse 
in CLL patients who showed the high prognostic value 
independent from del[17p]. 4.5% of untreated patients 
with CLL have TP53 mutations in the absence of del[17p]. 
Mutations in TP53 are detected in about 10%-15% of 
patients with CLL at diagnosis, and 30 % on combination 
with del[17p] [83]. p53 deregulation alone or concomitant 
with del[17p] is reported to be a significant factor in 
the effective treatment option for these patients [89]. 
Additionally, the ATM components of the DNA damage 
pathway was observed to be deregulated in B-CLL cells 
and might underlie refractory disease [63, 89]. 
The extrinsic apoptosis is triggered by binding the 
tumour necrosis factor receptors (TNF-Rs) with members 
of TNF family ligands (TNF-a, FasL, and TRAIL) 
[74]. Computational modeling of the extrinsic apoptotic 
pathway revealed key regulators of TNF-mediated 
apoptosis. Particularly important role plays the positive 
feedback in the bistability dynamics of apoptotic signals 
(i.e. all-or-none behaviour) and irreversibility in caspase 
activation, as well as multi-factorial controlling type I 
versus II apoptosis pathways [74, 75, 105, 106, 109-112]. 
Sensitivity analysis of TNF-mediated apoptosis models 
aimed at identifying control points in apoptotic signalling 
[75, 103, 107, 109-111, 113]. The results of sensitivity 
analysis of the computational models of apoptosis induced 
by TRAIL [114] and FasL [75] are given in figure 4A and 
B, respectively.
The high level of sensitivity of the model output 
(caspase-3 activation) showed the following sensitive 
points of this pathway: 1. kinetic parameters of TRAIL 
ligand-TRAIL receptor interaction and concentrations 
of membrane receptors; 2. activation of pro-apoptotic 
protein Bak/Bax negatively regulated by Bcl-2 protein; 
and 3. Smac/XIAP inhibition of caspase-3 and caspase-9 
resulting in positive feedback in apoptosis. The sensitivity 
of caspase-3 activation to Bcl-2 concentration was obtained 
at upregulation of Bcl-2 as opposed to insensitivity to 
Bcl-2 at downregulation of Bcl-2 when Bcl-2 does not 
inhibit the type II apoptotic pathway significantly (see 
the representation of the sensitivity coefficients at the 
decrease and increase of protein expression levels in 
figure 4B) [75]. This finding is in agreement with clinical 
data on the significant role of Bcl-2 in B-CLL [89]. The 
B-CLL cells, acquire survival benefit against apoptotic 
signals, and resistance to therapy by upregulation of Bcl-
2 [87]. Overexpression of Bcl-2 is considered as one of 
the biomarkers of CLL and a promising therapeutic target 
in CLL therapy as alone and in combination. Inhibition 
of Bcl-2 protein family activates programmed cell death 
through initiation of the mitochondrial pathway of 
apoptosis. Now several therapeutic agents targeting Bcl-2 
family of proteins are in clinical development. Oblimersen 
(Bcl-2 antisense oligonucleotide) is at phase III trial and 
small-molecular mimetics of the BH3 peptide domain 
of Bcl-2 (obatoclax, navitoclax) are being clinically 
evaluated in patients with repulsed/refractory CLL [89, 
115]. The different sensitivity of mitochondrial apoptotic 
pathway towards down-regulation and up-regulation of 
Bcl-2 revealed in sensitivity analysis showed that Bcl-
2 inhibitors can possess selectivity for CLL cells versus 
healthy cells with a normal expression of Bcl-2 [75]. 
High sensitivity of caspase-3 activation with the 
affinity of TRAIL ligand to TRAIL receptor and their 
concentrations obtained in sensitivity analysis (figure 
4), correlates with a significant role of the death receptor 
in initiation of apoptosis in B-CLL cells [101]. It was 
observed that CLL cells manifest resistance to TRAIL-
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Figure 4. Sensitivity analysis of the apoptosis models. (A) Results of sensitivity analysis of the model of TRAIL-induced apoptosis to 
kinetic parameters of the model: the rates of the forward, kf and reverse reactions, kr [108]. (B) Results of sensitivity analysis of the model 
of FasL-induced apoptosis to concentration of the proteins involved [69]. Data represent the change in the half-time of caspase-3 activation 
(hour) at the variation of protein level two orders of magnitude in either direction from the baseline values. Abbreviations: Fas - FAS receptor, 
FasL- Fas ligand; XIAP - X-linked inhibitor of apoptosis protein, FADD - Fas-associated protein with death domain, casp3 - a caspase-3 
protein, casp9 - a caspase-9 protein, casp8 - a caspase-8 protein, cytoC - cytochrome c, FLIP - flice inhibitory protein, Bax - Bcl-2 associated 
X protein, Bcl-2 - B-cell lymphoma 2 protein, Bid - BH3 interacting domain death agonist, TRAIL- TNF-related apoptosis-inducing ligand, 
TRAIL-R – TRAIL receptor, Smac - second mitochrondria-derived activator of caspase, Apaf-1 - apoptotic protease activating factor-1. Data 
are represented by kind permission of Prof. Z. Sun (A) and Prof. D.A. Lauffenburger (B).
induced apoptosis due to a low surface expression of 
death receptors, or over-expression of inhibitory proteins 
such as FLIP, IAP2, and XIAP [101, 116]. Sensitising 
B-CLL cells to TRAIL-induced apoptosis is possible 
by up-regulating surface expression of death receptors 
or down-regulating the inhibitory proteins [101]. 
Targeting TRAIL receptors by anti-TRAIL-R1 antibody, 
mapatumumab also showed in vitro efficacy in different 
haematological malignancies [101]. Apart from pro-
apoptotic signaling, the TNF-family receptors activate 
pro-survival signaling cascades, mainly through the NF-
kB pathway [89, 117]. 
The decision making in cell survival/apoptosis is 
determined by the balance between these competing 
signals. Two ligands that belong to the TNF superfamily, 
BAFF (B-cell–activating factor), APRIL (a proliferation-
inducing ligand), and their receptors, were reported to be 
key regulators of B-CLL cell survival [89]. Receptors of 
BAFF and APRIL are expressed on B-CLL cells, and when 
activated can promote B-CLL cell survival. The release 
of BAFF and APRIL through an autocrine mechanism 
is reported to cause the constitutive activation of both 
the canonical and noncanonical NF-κB pathways [117, 
118]. Computational modelling of NF-κB pathway was 
carried out to elucidate specific mechanisms governing 
NF-κB-induced gene expression, as in part-mechanisms 
of oscillatory dynamics in this pathway [104, 113, 119-
121]. Sensitivity analysis of NF-κB pathway models 
revealed that formation and function of the inhibitor IκB 
kinase complex (IKK), significantly impact on the NF-
κB signalling: [104, 119, 120]. The inhibitors of IKKb 
that inhibit canonical NF-κB pathway are expected to 
be attractive targets for B-CLL therapy [117]. In in vitro 
testing of the action of IKKb inhibitor, UTC on B-CLL 
cells showed suppression of the protective effects of 
BAFF on B-CLL cell survival [117]. The other therapeutic 
approach to inactivate pro-survival NF-κB pathway in 
B-CLL cells is developing, and in part designing, a fusion 
protein targeting both BAFF and APRIL ligands [89, 
122]. In addition, novel compounds with pro-apoptotic 
activity should also be considered as potential for potential 
treatment of B-CLL patients [123, 124].
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8. Concluding remarks and perspectives
Building regulatory network model is based on 
establishing the dynamics of interaction networks 
showing regulatory pathways involved in gene regulation 
during the cell cycle and apoptosis. These network 
models only form a very small part in terms of calibrating 
of the models, this can be done using patient samples to 
produce data in terms of the quantitative measurement 
of key regulatory proteins and cytokine profiling. Once 
calibrated on an individual patient basis, the models 
would then enable monitoring of that patient to determine 
significant changes in the molecular phenotype and, in 
terms of therapy, permit intervention therapies to be 
designed using a broad range of bio-therapeutic drugs. A 
multi-target approach would be possible by identifying 
key regulators that over come drug resistance trigger 
apoptosis. Moreover by determining sensitivity nodes 
or fragile points to induce apoptosis in B-CLL cells, can 
be useful as a robust drug sensitivity reporter model. 
These models can result in achieving maximum benefit 
in treatment regimes for B-CLL patients. Due to the 
inherent complexity however, particularly in regard to 
the number of regulatory feedback loops, we believe 
that a successful approach can only be achieved using 
mathematical methods.
Modelling the cell cycle has been shown to be 
extremely robust in terms of the parameter variations. 
Experimental and clinical data support the hypothesis 
that computationally identified fragile interactions in the 
cell cycle represent promising targets for drug therapy 
[89]. Modulation of translational efficiency and the 
manipulation of programmed proteolysis are the key 
components of fragile mechanisms across all the models, 
and therefore these areas should be considered in model 
network development for prediction scores in B-CLL 
disease in order to reach an appropriate therapeutic 
decision in patient treatment. Once the model satisfies 
the parameters such as sensitivity, robustness and fragile 
point determination, this can be applied for prediction 
of selective drug targets and treatment outcome. It is 
known that B-CLL is a slowly progressing disease. 
This allows drug selectivity of single or combination 
of therapeutic agents to be predicted using a model and 
then drug combinations to be tested on B-CLL ex vivo 
culture obtained form patient. As well as being useful 
for developing new therapies, the described models 
might be useful in establishing the causes of B-CLL. 
For example it may be that an antigen, either foreign 
or perceived foreign is involved, and the models could 
be used to further investigate molecular mechanism of 
the disease. It is also possible that the B-CLL phenotype 
covers a number of disease sub-types and hence the 
modelling approach would enable some of these sub-
types to be described, thus leading to improved diagnosis 
and personalised therapies.
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